Cart
sales@molnova.com
SR 16832
CAS No. 2088135-12-8
SR 16832( SR-16832 | SR16832 )
Catalog No. M27795 CAS No. 2088135-12-8
SR 16832 is a dual-site PPARγ inhibitor. It also inhibits the binding of endogenous ligands and transcriptional activity of PPARγ, more effectively than the orthosteric covalent antagonist GW 9662 and T 0070907.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 272 | In Stock |
|
| 10MG | 402 | In Stock |
|
| 25MG | 664 | In Stock |
|
| 50MG | 888 | In Stock |
|
| 100MG | 1242 | In Stock |
|
| 500MG | 2511 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSR 16832
-
NoteResearch use only, not for human use.
-
Brief DescriptionSR 16832 is a dual-site PPARγ inhibitor. It also inhibits the binding of endogenous ligands and transcriptional activity of PPARγ, more effectively than the orthosteric covalent antagonist GW 9662 and T 0070907.
-
DescriptionSR 16832 is a dual-site PPARγ inhibitor. It also inhibits the binding of endogenous ligands and transcriptional activity of PPARγ, more effectively than the orthosteric covalent antagonist GW 9662 and T 0070907.
-
In Vitro——
-
In Vivo——
-
SynonymsSR-16832 | SR16832
-
PathwayMetabolic Enzyme/Protease
-
TargetPPAR
-
RecptorP2X7
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2088135-12-8
-
Formula Weight357.75
-
Molecular FormulaC17H12ClN3O4
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 250 mg/mL (698.81 mM)
-
SMILESCOc1ccc2nccc(NC(=O)c3cc(ccc3Cl)[N+]([O-])=O)c2c1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Stock TC, et al. Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate. J Rheumatol. 2012 Apr;39(4):720-7.
molnova catalog
related products
-
Dihydrocurcumin
Dihydrocurcumin is the main metabolite of curcumin, which can reduce fat accumulation and oxidative stress response.
-
Oroxin A (b)
Oroxin A is a partial PPARγ agonist that can activate PPARγ transcriptional activation in vitro and in vivo. Oroxin A also exhibited inhibitory activity against α-glucosidase and antioxidant capacity.
-
Ragaglitazar
Ragaglitazar(NNC-61-0029) is a potent dual activator of PPARγ and PPARα, which shows improved insulin sensitization and lipid-lowering potential in animal models and can be used to study type 2 diabetes.
